INITIAL OBSERVATIONS OF ABLYNX'S PHASE II TTP PROGRAMME PRESENTED AT ISTH CONGRESS

(Thomson Reuters ONE) -


GHENT, Belgium, 28 July 2011 - Ablynx [Euronext Brussels: ABLX] today announced
that initial observations of the on-going Phase II study with the anti-von
Willebrand factor (vWF) Nanobody ALX-0081/ALX-0681 in patients with thrombotic
thrombocytopenic purpura (TTP) were presented at the 13(th) Congress of the
International Society on Thrombosis and Haemostasis (ISTH) in Kyoto, Japan.

The presentation only includes initial findings and the data should not be
extrapolated for the overall study.

The data were presented by principal investigator, Dr. Flora Peyvandi (IRCCS
Maggiore Hospital Foundation, University of Milan), and included the study
design and goal, and the initial observations from the first five patients that
were enrolled in the trial. These were two men and three women, aged 31 to 60
years. Four patients experienced their first episode of TTP and one patient had
a history of recurrent TTP.

Three patients received Nanobody treatment, the other two received placebo
treatment. Four patients have completed the study treatment. Biological activity
of the Nanobody was confirmed by a decrease of the biomarker RICO compared with
placebo. Two serious adverse events occurred, but were resolved, with one
subject discontinuing treatment.

Recruitment of the Phase II study is currently ongoing and final data are
expected during the course of 2013 with a Marketing Authorisation Application
(MAA) filing in Europe planned end 2013, if the Phase II study is accepted as
pivotal.


For more information, please contact Ablynx:
Dr Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
     +32 (0)473 39 50 68
e: edwin.moses(at)ablynx.com

Marieke Vermeersch
Investor Relations Manager

t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch(at)ablynx.com





Complete version of the press release:
http://hugin.info/137912/R/1533110/466968.pdf




This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Ablynx via Thomson Reuters ONE

[HUG#1533110]

Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 28.07.2011 - 18:00 Uhr
Sprache: Deutsch
News-ID 56813
Anzahl Zeichen: 2787

contact information:
Town:

Ghent

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 173 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"INITIAL OBSERVATIONS OF ABLYNX'S PHASE II TTP PROGRAMME PRESENTED AT ISTH CONGRESS"
steht unter der journalistisch-redaktionellen Verantwortung von

Ablynx (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Publication in Accordance With Article 14 of the Belgian Law of 2 May 2007 Regar ...

GHENT, BELGIUM -- (Marketwired) -- 08/27/13 -- (EURONEXT BRUSSELS: ABLX) today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to tr ...

Ablynx Announces Half-Year Results for 2013 ...

GHENT, BELGIUM -- (Marketwired) -- 08/21/13 -- (EURONEXT BRUSSELS: ABLX) today announced its results for the six-month period ending 30 June 2013, which have been prepared in accordance with the IAS 34 "Interim Financial Reporting" as adop ...

Ablynx Announces Warrant Exercise ...

GHENT, BELGIUM -- (Marketwired) -- 07/23/13 -- (EURONEXT BRUSSELS: ABLX) today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 273,913 common shares have been issued by the ...

Alle Meldungen von Ablynx